Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical

Drug Profile

Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical

Alternative Names: LJPC-6417

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class
  • Mechanism of Action Bone morphogenetic protein receptor type I antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrodysplasia ossificans progressiva

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Fibrodysplasia-ossificans-progressiva in USA
  • 18 Apr 2013 Early research in Fibrodysplasia ossificans progressiva in USA (unspecified route)
  • 18 Apr 2013 Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical receives Orphan Drug status for Fibrodysplasia ossificans progressiva in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top